SE9704869D0 - New pharmaceutical formulaton II - Google Patents

New pharmaceutical formulaton II

Info

Publication number
SE9704869D0
SE9704869D0 SE9704869A SE9704869A SE9704869D0 SE 9704869 D0 SE9704869 D0 SE 9704869D0 SE 9704869 A SE9704869 A SE 9704869A SE 9704869 A SE9704869 A SE 9704869A SE 9704869 D0 SE9704869 D0 SE 9704869D0
Authority
SE
Sweden
Prior art keywords
atpase inhibitor
formulaton
dosage form
new pharmaceutical
extended
Prior art date
Application number
SE9704869A
Other languages
English (en)
Swedish (sv)
Inventor
Per Gunnar Karehill
Per Johan Lundberg
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9704869A priority Critical patent/SE9704869D0/xx
Publication of SE9704869D0 publication Critical patent/SE9704869D0/xx
Priority to ZA9811239A priority patent/ZA9811239B/xx
Priority to ARP980106244A priority patent/AR017201A1/es
Priority to TW087120440A priority patent/TWI249410B/zh
Priority to MA25383A priority patent/MA26576A1/fr
Priority to DZ980295A priority patent/DZ2685A1/fr
Priority to TNTNSN98229A priority patent/TNSN98229A1/fr
Priority to CNB988136163A priority patent/CN1171582C/zh
Priority to BR9814378-6A priority patent/BR9814378A/pt
Priority to NZ505127A priority patent/NZ505127A/xx
Priority to CZ20002314A priority patent/CZ299228B6/cs
Priority to KR1020007006908A priority patent/KR100755154B1/ko
Priority to DK98964631T priority patent/DK1043976T3/da
Priority to PCT/SE1998/002368 priority patent/WO1999032091A1/fr
Priority to EP98964631A priority patent/EP1043976B1/fr
Priority to EEP200000383A priority patent/EE04901B1/xx
Priority to US09/555,744 priority patent/US6605303B1/en
Priority to KR1020067016717A priority patent/KR20060097069A/ko
Priority to CA002315261A priority patent/CA2315261C/fr
Priority to SK807-2000A priority patent/SK284988B6/sk
Priority to TR2000/01981T priority patent/TR200001981T2/xx
Priority to SI9830818T priority patent/SI1043976T1/sl
Priority to YU36700A priority patent/YU36700A/sh
Priority to AT98964631T priority patent/ATE312602T1/de
Priority to JP2000525083A priority patent/JP4865945B2/ja
Priority to IL13682798A priority patent/IL136827A0/xx
Priority to UA2000063360A priority patent/UA69397C2/uk
Priority to DE69832816T priority patent/DE69832816T2/de
Priority to ES98964631T priority patent/ES2252875T3/es
Priority to PL98341428A priority patent/PL193776B1/pl
Priority to HU0101437A priority patent/HUP0101437A3/hu
Priority to RU2000116011/14A priority patent/RU2214232C2/ru
Priority to AU19912/99A priority patent/AU759634B2/en
Priority to MYPI98005796A priority patent/MY126555A/en
Priority to SA99191077A priority patent/SA99191077B1/ar
Priority to IS5524A priority patent/IS5524A/is
Priority to HR20000380A priority patent/HRP20000380B1/xx
Priority to IL136827A priority patent/IL136827A/en
Priority to NO20003218A priority patent/NO20003218L/no
Priority to BG104620A priority patent/BG65028B1/bg
Priority to HK01105069A priority patent/HK1034455A1/xx
Priority to CY20061100346T priority patent/CY1106072T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SE9704869A 1997-12-22 1997-12-22 New pharmaceutical formulaton II SE9704869D0 (sv)

Priority Applications (42)

Application Number Priority Date Filing Date Title
SE9704869A SE9704869D0 (sv) 1997-12-22 1997-12-22 New pharmaceutical formulaton II
ZA9811239A ZA9811239B (en) 1997-12-22 1998-12-08 Oral pharmaceutical extended release dosage form
ARP980106244A AR017201A1 (es) 1997-12-22 1998-12-09 Forma de dosificacion farmaceutica entericamente recubierta de liberacion prolongada de un inhibidor de h+, k+ -atpasa, procedimiento para su manufactura,uso de la forma de dosificacion farmaceutica y uso del inhibidor para preparar un medicamento
TW087120440A TWI249410B (en) 1997-12-22 1998-12-09 Enteric coated pharmaceutical extended release dosage form of a H+, K+-ATPase inhibitor
MA25383A MA26576A1 (fr) 1997-12-22 1998-12-11 Formulation pharmaceutique orale a liberation prolongee
DZ980295A DZ2685A1 (fr) 1997-12-22 1998-12-16 Formulation pharmaceutique orale à libération prolongée.
TNTNSN98229A TNSN98229A1 (fr) 1997-12-22 1998-12-16 Formulation pharmaceutique orale a liberation prolongee
AU19912/99A AU759634B2 (en) 1997-12-22 1998-12-17 Oral pharmaceutical extended release dosage form
TR2000/01981T TR200001981T2 (tr) 1997-12-22 1998-12-17 Farmasötik açıdan salınımı uzatılmış oral dozaj şekli
JP2000525083A JP4865945B2 (ja) 1997-12-22 1998-12-17 経口の延長放出性医薬品剤形
NZ505127A NZ505127A (en) 1997-12-22 1998-12-17 Oral pharmaceutical extended release dosage form of proton pump inhibitor
CZ20002314A CZ299228B6 (cs) 1997-12-22 1998-12-17 Orální farmaceutická dávková forma s prodlouženýmuvolnováním
KR1020007006908A KR100755154B1 (ko) 1997-12-22 1998-12-17 경구용 제약학적 서방형 투여 제형
DK98964631T DK1043976T3 (da) 1997-12-22 1998-12-17 Oral farmaceutisk doseringsform med langvarig frigivelse
PCT/SE1998/002368 WO1999032091A1 (fr) 1997-12-22 1998-12-17 Forme posologique pharmaceutique orale a liberation prolongee
EP98964631A EP1043976B1 (fr) 1997-12-22 1998-12-17 Forme posologique pharmaceutique orale a liberation prolongee
EEP200000383A EE04901B1 (et) 1997-12-22 1998-12-17 Peroraalne farmatseutiline pikendatud vabanemisega annusvorm
US09/555,744 US6605303B1 (en) 1997-12-22 1998-12-17 Oral pharmaceutical extended release dosage form
KR1020067016717A KR20060097069A (ko) 1997-12-22 1998-12-17 경구용 제약학적 서방형 투여 제형
CA002315261A CA2315261C (fr) 1997-12-22 1998-12-17 Forme posologique pharmaceutique orale a liberation prolongee
SK807-2000A SK284988B6 (sk) 1997-12-22 1998-12-17 Orálna farmaceutická dávková forma s predĺženým uvoľňovaním
CNB988136163A CN1171582C (zh) 1997-12-22 1998-12-17 口服药用延释剂型
SI9830818T SI1043976T1 (sl) 1997-12-22 1998-12-17 Oralna farmacevtska dozirna oblika s podaljsanim sproscanjem
YU36700A YU36700A (sh) 1997-12-22 1998-12-17 Oralni farmaceutski oblik za doziranje sa produženim oslobađanjem
AT98964631T ATE312602T1 (de) 1997-12-22 1998-12-17 Orale pharmazeutische dosierungsform mit verlängerter wirkstofffreisetzung
BR9814378-6A BR9814378A (pt) 1997-12-22 1998-12-17 Forma de dosagem de liberação prolongada farmacêutica revestida entérica de um inibidor de h+, k+-atpase, processos para a manufatura da mesma, para melhorar a inibição de secreção de ácido gástrico, para melhorar o efeito terapêutico no tratamento de distúrbios gastrointentinais, para receber um perfil de plasma prolongado de um inibidor da h+, k+-atpase, e, usos de uma composição farmacêutica e de inibidor da h+, k+-atpase
IL13682798A IL136827A0 (en) 1997-12-22 1998-12-17 Oral pharmaceutical extended release dosage form
UA2000063360A UA69397C2 (uk) 1997-12-22 1998-12-17 ПЕРОРАЛЬНА ДОЗОВАНА ФАРМАЦЕВТИЧНА ФОРМА ПОДОВЖЕНОЇ ДІЇ ІНГІБІТОРА Н<sup>+</sup>,К<sup>+</sup>,-АТФ-АЗИ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА СПОСІБ ЛІКУВАННЯ
DE69832816T DE69832816T2 (de) 1997-12-22 1998-12-17 Orale pharmazeutische dosierungsform mit verlängerter wirkstofffreisetzung
ES98964631T ES2252875T3 (es) 1997-12-22 1998-12-17 Forma de dosificacion farmaceutica oral de libeeracion prolongada.
PL98341428A PL193776B1 (pl) 1997-12-22 1998-12-17 Farmaceutyczna postać dawkowana z powłoczką jelitową o przedłużonym uwalnianiu inhibitora H, K-ATPazy, jej zastosowanie i sposób wytwarzania
HU0101437A HUP0101437A3 (en) 1997-12-22 1998-12-17 Oral pharmaceutical extended release dosage form
RU2000116011/14A RU2214232C2 (ru) 1997-12-22 1998-12-17 Пероральная фармацевтическая лекарственная форма с продолжительным высвобождением
MYPI98005796A MY126555A (en) 1997-12-22 1998-12-21 Oral pharmaceutical extended release dosage form
SA99191077A SA99191077B1 (ar) 1997-12-22 1999-02-17 صورة لجرعة صيدلانية طويلة المفعول تعطى عن طريق الفم
IS5524A IS5524A (is) 1997-12-22 2000-06-08 Forðatöflur til inntöku
HR20000380A HRP20000380B1 (en) 1997-12-22 2000-06-08 Oral pharmaceutical extended release dosage form
IL136827A IL136827A (en) 1997-12-22 2000-06-15 Pharmaceutical dosage form for oral administration with prolonged release
NO20003218A NO20003218L (no) 1997-12-22 2000-06-21 Oral farmasøytisk doseringsform med forlenget frigivningsvirkning
BG104620A BG65028B1 (bg) 1997-12-22 2000-07-17 Орална фармацевтична дозирана форма с удължено освобождаване
HK01105069A HK1034455A1 (en) 1997-12-22 2001-07-19 Oral pharmaceutical extended release dosage form.
CY20061100346T CY1106072T1 (el) 1997-12-22 2006-03-13 Φαρμακευτικη μορφη δοσης παρατεταμενης αποδεσμευσης απο του στοματος

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9704869A SE9704869D0 (sv) 1997-12-22 1997-12-22 New pharmaceutical formulaton II

Publications (1)

Publication Number Publication Date
SE9704869D0 true SE9704869D0 (sv) 1997-12-22

Family

ID=20409571

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9704869A SE9704869D0 (sv) 1997-12-22 1997-12-22 New pharmaceutical formulaton II

Country Status (39)

Country Link
US (1) US6605303B1 (fr)
EP (1) EP1043976B1 (fr)
JP (1) JP4865945B2 (fr)
KR (2) KR100755154B1 (fr)
CN (1) CN1171582C (fr)
AR (1) AR017201A1 (fr)
AT (1) ATE312602T1 (fr)
AU (1) AU759634B2 (fr)
BG (1) BG65028B1 (fr)
BR (1) BR9814378A (fr)
CA (1) CA2315261C (fr)
CY (1) CY1106072T1 (fr)
CZ (1) CZ299228B6 (fr)
DE (1) DE69832816T2 (fr)
DK (1) DK1043976T3 (fr)
DZ (1) DZ2685A1 (fr)
EE (1) EE04901B1 (fr)
ES (1) ES2252875T3 (fr)
HK (1) HK1034455A1 (fr)
HR (1) HRP20000380B1 (fr)
HU (1) HUP0101437A3 (fr)
IL (2) IL136827A0 (fr)
IS (1) IS5524A (fr)
MA (1) MA26576A1 (fr)
MY (1) MY126555A (fr)
NO (1) NO20003218L (fr)
NZ (1) NZ505127A (fr)
PL (1) PL193776B1 (fr)
RU (1) RU2214232C2 (fr)
SA (1) SA99191077B1 (fr)
SE (1) SE9704869D0 (fr)
SK (1) SK284988B6 (fr)
TN (1) TNSN98229A1 (fr)
TR (1) TR200001981T2 (fr)
TW (1) TWI249410B (fr)
UA (1) UA69397C2 (fr)
WO (1) WO1999032091A1 (fr)
YU (1) YU36700A (fr)
ZA (1) ZA9811239B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ318501A (en) * 1995-09-21 1999-06-29 Pharma Pass Llc Novel composition containing an acid-labile omeprazole and process for its preparation
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
WO1999029299A1 (fr) 1997-12-08 1999-06-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Nouvelle forme de suppositoire renfermant un compose actif acidolabile
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
WO2002032427A1 (fr) * 2000-10-20 2002-04-25 Galephar M/F Formulation stable administrable par voie orale contenant un derive de benzimidazole
PT1341528E (pt) * 2000-12-07 2012-03-20 Nycomed Gmbh Comprimido de desintegração rápida compreendendo um ingrediente activo lábil a ácido
JP4848101B2 (ja) * 2001-08-17 2011-12-28 株式会社フジモト・コーポレーション 徐放性マイクロペレット
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
EP1815868A3 (fr) * 2002-09-26 2007-08-15 Astellas Pharma Inc. Agent améliorant l'absorption de médicaments
EP2596792A1 (fr) 2002-10-16 2013-05-29 Takeda Pharmaceutical Company Limited Préparations solides stables
JP4493970B2 (ja) * 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
US8980322B2 (en) 2003-03-17 2015-03-17 Takeda Pharmaceutical Company Limited Controlled release composition
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
WO2005012289A1 (fr) * 2003-07-17 2005-02-10 Altana Pharma Ag Nouveau sel de (r) - pantoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
FR2861990B1 (fr) * 2003-11-10 2006-02-10 Nouveaux Produits Pharma Comprimes faiblement doses a reseau de polymeres
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2469427A1 (fr) * 2004-06-01 2005-12-01 Pharmascience Inc. Forme pharmaceutique mixte a l'etat sec contenant des derives de benzimidazole
EP1768668A2 (fr) * 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Forme posologique a doses ppi multiples
US20090124702A1 (en) * 2005-01-25 2009-05-14 Pechetti Siva Satya Krishna Babu Pharmaceutical Compositions of Metformin
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
DE102005060393A1 (de) * 2005-12-16 2007-06-21 Add Advanced Drug Delivery Technologies Ltd. Orales Präparat mit kontrollierter Freisetzung
CN101389316A (zh) * 2005-12-28 2009-03-18 武田药品工业株式会社 控制释放固体制剂
WO2007138606A2 (fr) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Formulation pharmaceutique comprenant des unités multiples
US20080181932A1 (en) * 2007-01-30 2008-07-31 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
WO2008112388A1 (fr) 2007-03-14 2008-09-18 Drugtech Corporation Agencement spatial de particules dans un dispositif servant a boire, pour l'administration orale d'agents pharmaceutiques
KR20170097787A (ko) * 2007-10-12 2017-08-28 다케다 파마슈티칼스 유에스에이, 인코포레이티드 음식 섭취와 관계없이 위장 장애를 치료하는 방법
US12011423B2 (en) 2007-11-06 2024-06-18 Foraviset Ltd. S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders
EP2405898A2 (fr) 2009-03-09 2012-01-18 Council Of Scientific & Industrial Research Composition à libération lente d'un agent thérapeutique
US20140127296A1 (en) * 2012-11-05 2014-05-08 Kenneth John Tibbs Pharmaceutical preparation and method for treatment of diabetes
DK2956149T3 (da) * 2013-02-13 2019-09-09 Redhill Biopharma Ltd Farmaceutiske sammensætninger til behandling af helicobacter pylori
CN104721185A (zh) * 2013-12-21 2015-06-24 辰欣药业股份有限公司 一种提高埃索美拉唑钠稳定性的方法
EP3288556A4 (fr) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Compositions à désintégration par voie orale
WO2017145146A1 (fr) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprenant des inhibiteurs de la pompe à protons
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10729735B1 (en) 2016-09-14 2020-08-04 Phoenix Biotechnology, Inc. Method and compostitions for treating coronavirus infection
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
AU4640985A (en) * 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
US5229181A (en) * 1990-10-30 1993-07-20 Amber Technologies Tubular knit cleanroom wiper
TW209174B (fr) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
IT1251153B (it) 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
ES2179829T3 (es) * 1992-09-18 2003-02-01 Yamanouchi Pharma Co Ltd Preparacion de hidrogel de liberacion prolongada.
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
JPH07330629A (ja) * 1994-06-02 1995-12-19 Nippon Shokubai Co Ltd 徐放性製剤
MX9600857A (es) * 1994-07-08 1997-06-28 Astra Ab Forma de dosificacion i en tabletas, con unidades multiples.
HUT78132A (hu) * 1994-07-08 2000-06-28 Astra Aktiebolag Omeprazol magnéziumsóját tartalmazó új orális gyógyszerforma
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
WO1997047285A1 (fr) * 1996-06-10 1997-12-18 Depomed, Inc. Systeme a caracteristiques de retention renforcees pour l'administration controlee par voie orale de medicaments a retention gastrique
SE9602442D0 (sv) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US7016717B2 (en) * 2002-07-05 2006-03-21 The Regents Of The University Of California Near-infrared spectroscopic tissue imaging for medical applications
ITPD20050230A1 (it) * 2005-07-28 2007-01-29 Marcato Spa Macchina ad uso domestico per la estrusione di paste alimentari fresche

Also Published As

Publication number Publication date
DE69832816D1 (de) 2006-01-19
KR20010033428A (ko) 2001-04-25
JP4865945B2 (ja) 2012-02-01
DZ2685A1 (fr) 2003-03-29
HRP20000380B1 (en) 2007-08-31
CZ299228B6 (cs) 2008-05-21
CA2315261C (fr) 2008-02-12
SK8072000A3 (en) 2001-01-18
EP1043976B1 (fr) 2005-12-14
EP1043976A1 (fr) 2000-10-18
ES2252875T3 (es) 2006-05-16
WO1999032091A1 (fr) 1999-07-01
IS5524A (is) 2000-06-08
JP2001526211A (ja) 2001-12-18
EE04901B1 (et) 2007-10-15
NO20003218D0 (no) 2000-06-21
SK284988B6 (sk) 2006-04-06
KR20060097069A (ko) 2006-09-13
BG104620A (en) 2001-04-30
HK1034455A1 (en) 2001-10-26
ZA9811239B (en) 1999-06-22
TR200001981T2 (tr) 2000-11-21
AU1991299A (en) 1999-07-12
DE69832816T2 (de) 2006-08-31
RU2214232C2 (ru) 2003-10-20
NO20003218L (no) 2000-08-22
PL341428A1 (en) 2001-04-09
UA69397C2 (uk) 2004-09-15
CZ20002314A3 (cs) 2000-11-15
AR017201A1 (es) 2001-08-22
ATE312602T1 (de) 2005-12-15
CY1106072T1 (el) 2011-06-08
KR100755154B1 (ko) 2007-09-04
EE200000383A (et) 2001-12-17
TNSN98229A1 (fr) 2005-03-15
CA2315261A1 (fr) 1999-07-01
CN1171582C (zh) 2004-10-20
CN1284866A (zh) 2001-02-21
HRP20000380A2 (en) 2001-06-30
DK1043976T3 (da) 2006-03-20
BG65028B1 (bg) 2006-12-29
IL136827A (en) 2007-05-15
MA26576A1 (fr) 2004-12-20
MY126555A (en) 2006-10-31
IL136827A0 (en) 2001-06-14
PL193776B1 (pl) 2007-03-30
HUP0101437A3 (en) 2003-01-28
NZ505127A (en) 2003-02-28
SA99191077B1 (ar) 2006-07-11
US6605303B1 (en) 2003-08-12
BR9814378A (pt) 2000-10-10
YU36700A (sh) 2003-01-31
HUP0101437A2 (hu) 2001-10-28
AU759634B2 (en) 2003-04-17
TWI249410B (en) 2006-02-21

Similar Documents

Publication Publication Date Title
SE9704869D0 (sv) New pharmaceutical formulaton II
NZ509028A (en) Stable extended release oral dosage composition comprising a pseudoephedrine-containing core, the core being uniformly covered with a desloratadine-containing film
DE69805001T2 (de) Osmotische darreichungsform mit zwei mantelschichten
DK1276470T3 (da) Smagskaskerende overtrækssammensætning
AU7031500A (en) Therapeutic quinazoline compounds
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
GEP20033014B (en) Enteric Coated Pharmaceutical Composition and Method of Manufacturing
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
GB0007419D0 (en) Composition
NO20016346D0 (no) Ny formulering
BR0013935A (pt) IsÈmeros oticamente ativos de cetotifeno e metabólitos terapeuticamente ativos dos mesmos
BR9610480A (pt) Inibição do fator alfa de necrose tumoral
DE60235648D1 (de) Pharmazeutische metformintablette mit verlängerter freisetzung
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
NO20101070L (no) Fremgangsmate til dosering av et medikament, samt doseringsform
DE60102590T2 (de) Darreichungsformen zur behandlung von oralen mykosen
RS50298B (sr) Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina
SE8901003D0 (sv) Snabbloesliga preparat
PT858337E (pt) Composicao farmaceutica para o tratamento de doencas auto-imunes
AR002191A1 (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion, procedimiento para su preparacion
BRPI0307319B8 (pt) forma de dosagem oral para liberação controlada de droga e processo para sua preparação
DE69813681D1 (de) Neue triazole als therapeutische mittel gegen pilzinfektionen
ES2161809T3 (es) Uso de factor proliferativo osteoblastico.
FI991115A0 (fi) Menetelmä oraalisesti elimistöön tuotavan ravinteen tai muun fysiologisesti vaikuttavan aineen maittavuuden biokyberneettiseksi manipuloimiseksi sekä menetelmän käyttämiseen liittyvä valmiste